Tocilizumab and Thromboembolism in COVID-19: A Retrospective Hospital-Based Cohort Analysis

Background Tocilizumab, an interleukin-6 (IL-6) receptor antagonist, has been used in patients with coronavirus disease 2019 (COVID-19) as an anti-cytokine agent. IL-6 also plays a complex role in hemostasis and thrombosis. We observed a transient elevation of D-dimer in our patients who received to...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Kok Hoe, Patel, Bhavik, Podel, Bishnu, Szablea, Maria E, Shaaban, Hamid S, Guron, Gunwant, Slim, Jihad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220488/
https://www.ncbi.nlm.nih.gov/pubmed/34178527
http://dx.doi.org/10.7759/cureus.15208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220488/
https://www.ncbi.nlm.nih.gov/pubmed/34178527
http://dx.doi.org/10.7759/cureus.15208

Ejemplares similares